«Opdivo has become a foundational treatment that is transforming cancer care
across multiple tumor types,» chief executive Giovanni Caforio said in a statement.
Emerging date has shown that IDO1 is induced during tumor development and / or after immune checkpoint treatment
in multiple tumor types, helping malignant cells escape eradication by the immune system.
The protein, tyrosine kinase 6 (PTK6), is an enzyme molecule that is highly expressed
in multiple tumor types, including prostate, ovarian, and breast cancers.
Antibiotics that target mitochondria effectively eradicate cancer stem cells, across
multiple tumor types: treating cancer like an infectious disease.
Emerging evidence suggests that IDO1 is induced during tumor development or after immune checkpoint treatment in
multiple tumor types, helping malignant cells escape eradication by the immune system.
Also,
multiple tumor types might be present, and you can make the wrong interpretation with just this test.